68 related articles for article (PubMed ID: 20102407)
21. Her-2/neu gene amplification in paraffin-embedded tissue sections of meningioma patients.
Ozer O; Sahin FI; Aydemir F; Ozen O; Yilmaz Z; Altinörs N
Turk Neurosurg; 2009 Apr; 19(2):135-8. PubMed ID: 19431122
[TBL] [Abstract][Full Text] [Related]
22. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy.
Ross JS; Fletcher JA
Semin Cancer Biol; 1999 Apr; 9(2):125-38. PubMed ID: 10202134
[TBL] [Abstract][Full Text] [Related]
23. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients.
Morrison C; Zanagnolo V; Ramirez N; Cohn DE; Kelbick N; Copeland L; Maxwell GL; Fowler JM
J Clin Oncol; 2006 May; 24(15):2376-85. PubMed ID: 16710036
[TBL] [Abstract][Full Text] [Related]
24. Clinicopathological relevance of HER2/neu and a related gene-protein cubic regression correlation in colorectal adenocarcinomas in Taiwan.
Li JW; Chuang TC; Yang AH; Hsu CK; Kao MC
Int J Oncol; 2005 Apr; 26(4):933-43. PubMed ID: 15753987
[TBL] [Abstract][Full Text] [Related]
25. Her-2/neu expression and gene amplification in gastrinomas: correlations with tumor biology, growth, and aggressiveness.
Goebel SU; Iwamoto M; Raffeld M; Gibril F; Hou W; Serrano J; Jensen RT
Cancer Res; 2002 Jul; 62(13):3702-10. PubMed ID: 12097278
[TBL] [Abstract][Full Text] [Related]
26. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma.
Bell JG; Minnick A; Reid GC; Judis J; Brownell M
Gynecol Oncol; 1997 Sep; 66(3):388-92. PubMed ID: 9299250
[TBL] [Abstract][Full Text] [Related]
27. Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.
Sugimoto T; Koizumi T; Sudo T; Yamaguchi S; Kojima A; Kumagai S; Nishimura R
Kobe J Med Sci; 2007; 53(5):177-87. PubMed ID: 18204294
[TBL] [Abstract][Full Text] [Related]
28. HER-2/neu overexpression and hormone dependency in endometrial cancer: analysis of cohort and review of literature.
Mariani A; Sebo TJ; Katzmann JA; Riehle DL; Dowdy SC; Keeney GL; Lesnick TG; Podratz KC
Anticancer Res; 2005; 25(4):2921-7. PubMed ID: 16080545
[TBL] [Abstract][Full Text] [Related]
29. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
30. Effects of ectopic HER-2/neu gene expression on the COX-2/PGE2/P450arom signaling pathway in endometrial carcinoma cells: HER-2/neu gene expression in endometrial carcinoma cells.
Li S; Ma X; Ma L; Wang C; He Y; Yu Z
J Exp Clin Cancer Res; 2013 Mar; 32(1):11. PubMed ID: 23453006
[TBL] [Abstract][Full Text] [Related]
31. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas.
Vanden Bempt I; Vanhentenrijk V; Drijkoningen M; Wlodarska I; Vandenberghe P; De Wolf-Peeters C
Histopathology; 2005 Apr; 46(4):431-41. PubMed ID: 15810955
[TBL] [Abstract][Full Text] [Related]
32. [Correlation between receptor status and results of treatment in endometrial carcinoma].
Baĭnazarova AA; Iskakova ZhK
Vopr Onkol; 2006; 52(6):654-8. PubMed ID: 17338243
[TBL] [Abstract][Full Text] [Related]
33. The significance of HER-2/neu/c-erbB-2 gene amplification in benign and malignant breast disease.
Supanaranond K; Sukarayodhin S; Tanyakaset M; Balachandra K; Jullaksorn D; Rienkijkarn M; Hoisanka N; Tantivanich S
Southeast Asian J Trop Med Public Health; 1997 Sep; 28(3):631-40. PubMed ID: 9561622
[TBL] [Abstract][Full Text] [Related]
34. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization.
Persons DL; Borelli KA; Hsu PH
Mod Pathol; 1997 Jul; 10(7):720-7. PubMed ID: 9237184
[TBL] [Abstract][Full Text] [Related]
35. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Hanna W; Nofech-Mozes S; Kahn HJ
Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
[TBL] [Abstract][Full Text] [Related]
36. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Hirano M; Hayashida K; Mizumukai E; Nanaura H; Honda N
Oncol Rep; 2007 Nov; 18(5):1183-7. PubMed ID: 17914570
[TBL] [Abstract][Full Text] [Related]
37. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland.
Cornolti G; Ungari M; Morassi ML; Facchetti F; Rossi E; Lombardi D; Nicolai P
Arch Otolaryngol Head Neck Surg; 2007 Oct; 133(10):1031-6. PubMed ID: 17938328
[TBL] [Abstract][Full Text] [Related]
38. HER-2/neu gene amplification in ovarian tumours: a comprehensive immunohistochemical and FISH analysis on tissue microarrays.
Mayr D; Kanitz V; Amann G; Engel J; Burges A; Löhrs U; Diebold J
Histopathology; 2006 Jan; 48(2):149-56. PubMed ID: 16405663
[TBL] [Abstract][Full Text] [Related]
39. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
[TBL] [Abstract][Full Text] [Related]
40. The biology of erbB-2/neu/HER-2 and its role in cancer.
Hynes NE; Stern DF
Biochim Biophys Acta; 1994 Dec; 1198(2-3):165-84. PubMed ID: 7819273
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
